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Abstract
Background: Hereditary hemochromatosis (HH) is an autosomal recessive disorder mainly associated with
homozygosity for the C282Y and H63D mutations in the hemochromatosis (HFE) gene. The reports about the
C282Y and H63D mutations and hepatocellular carninoma (HCC) were controversial. To clarify the relationship
between C282Y and H63D mutations and HCC, a meta-analysis including nine studies (1102 HCC cases and 3766
controls, mainly came from European populations) was performed.
Methods: The association was measured using random-effect (RE) or fixed-effect (FE) odds ratios (ORs) combined
with 95% confidence intervals (CIs) according to the studies’ heterogeneity.
Results: Meta-analysis of nine studies showed that Y allele of C282Y was associated with HCC risk: RE OR reached
1.50 (95%CI: 1.05-2.14, p for heterogeneity = 0.02, I
2 = 0.57). Subgroup analysis of seven studies also showed Y
allele was associated with HCC risk in healthy populations: RE OR reached 1.61 (95%CI: 1.08-2.39, p for
heterogeneity = 0.04, I
2 = 0.55). We further did subgroup analysis in alcoholic liver cirrhosis (LC) patients of four
studies (224 cases and 380 controls) and found that both the dominant model and Y allele of C282Y were
associated with HCC risk (FE OR reached 4.06, 95%CI: 2.08-7.92 and 3.41, 95%CI: 1.81-6.41, respectively). There was
no distinct heterogeneity among the studies (I
2 = 0). Sensitivity analyses showed the results were robust in the
subgroup analysis of alcoholic LC patients.
Conclusions: C282Y mutation was associated with HCC in European alcoholic LC patients.
Background
Hepatocellular carninoma (HCC) is the fifth most com-
mon cancer in the world and the third most common
cause of cancer mortality [1]. Hereditary hemochroma-
tosis (HH) is an autosomal recessive genetic condition
in which excess iron is absorbed by the intestine and
deposited throughout the body [2]. If untreated, affected
individuals may accumulate excess iron over the many
years of their adult life, and this causes progressive tis-
sue damage [3]. It has been reported that HH may result
in many diseases, including liver disease (fibrosis, cirrho-
sis, and hepatocellular carcinoma). Some studies
reported that liver disease was the most common cause
of death of patients with HH [4,5].
In 1996, Feder and colleagues [6] showed that homo-
zygosity for mutation (C282Y, G>A, rs1800562) in the
HFE gene was responsible for the majority of cases of
typical phenotypic HH. The frequency of the second
variant (H63D, C>G, rs1799945) is also increased in HH
patients, but its penetrance is low. From then on, HFE
gene has been postulated as a candidate gene of HCC.
Some studies [7-16] demonstrated that C282Y or H63D
increased the risk of HCC, while some [17-19] gave
negative results. Some large scale cohort studies [20,21]
also showed that HFE gene mutation penetrance was
low and did not increase the likelihood of death from
any cause among the C282Y homozygotes compared
with subjects who had no C282Y mutation.
However, the estimates in these cohort studies were
conservative in the sense that in the cohort study per-
iod, a proportion of HH patients had received phlebot-
omy treatment. As a result, the role of C282Y and
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To clarify the relationship between HFE C282Y and
H63D mutations and HCC, a meta-analysis was
performed.
Methods
Study identification and selection
Eligible studies were identified by searching the data-
bases of PubMed and ISI Web of Knowledge for rele-
vant reports published before May 2009. The search
criteria “c282y OR h63d” and “liver cancer OR hepato-
cellular carcinoma” were used. We also searched reports
and dissection databases published in the Chinese Bio-
medical database (CBM), China National Knowledge
Infrastructure (CNKI), and Wan Fang (Chinese) data-
base to collect articles of case-control studies or cohort
studies on associations between HFE mutations and sus-
ceptibility to HCC before May 2009. The reference lists
of the retrieved articles were also reviewed to identify
additional articles missed by the above search.
Studies were selected if (1) there were available data
for at least one of the C282Y and H63D two mutations
with risk of HCC using a case-control or cohort design;
(2) HCC cases were diagnosed by histopathological
biopsy or by elevated AFP and distinct iconography
changes (CT, MRI, and B ultrasonography); (3) control
subjects were free of cancer. Controls could be com-
posed of healthy subjects, chronic liver disease (CLD),
including chronic hepatitis (CH) and LC. CLD was
either histologically proven or diagnosed based on con-
cordant clinical, biological, and morphological criteria.
Review articles and articles that did not provide geno-
type data were excluded.
Data extraction and synthesis
The following information was extracted from each
study: first author’s surname, year of publication, ethni-
city of study population, country where study was con-
ducted, and the number of cases and controls for each
C282Y and H63D genotype. When specific results were
not reported, we used available tabular data to calculate
them.
Statistical methods
To compare the odds ratio (OR) on the same baseline, we
used crude OR to conduct the meta-analysis. The effect of
association was indicated as crude OR with the corre-
sponding 95% confidence intervals (CIs). Because of rela-
tively small sample sizes of individual studies and low
frequency of variant alleles and the practical clinical value,
we performed meta-analysis only in two models: dominant
model (YY+CY vs. CC or DD+HD vs. HH) and allele con-
trast (Y vs. C or D vs. H). The pooled OR was estimated
using the FE model (DerSimonian & Laird) [22]. The
heterogeneity between studies was tested using the Q sta-
tistic [23]. If P < 0.10, the heterogeneity was considered
statistically significant, and the RE model was then used.
Heterogeneity was also quantified using the I
2 metric,
which is independent of the number of studies in the
meta-analysis (I
2 < 25% = no heterogeneity; I
2 = 25-50% =
moderate heterogeneity; I
2 > 50% = large or extreme het-
erogeneity) [24]. The potential small-study bias was tested
using the Egger regression test asymmetry [25] and the
Begg’s test for funnel plot, which is based on Kendall’s tau
[26]. Sensitivity analysis was performed by omitting one
study at a time to assess the influence of individual studies
on meta-analysis. The distribution of the genotypes in the
control group was tested for Hardy-Weinberg equilibrium
using a goodness-of-fit Chi-square test.
All analyses above were conducted using the STATA
version 10.0 software (Stata Corp, College Station,
Texas). All P-values were two-sided. A p value less than
0.05 was considered statistically significant.
The statistical power was calculated using the PS soft-
ware [27]. In order to assess the reliability of the posi-
tive association, we calculated false positive report
probability (FPRP) [28]. An Excel spreadsheet to calcu-
late FPRP is included with the online material http://
jncicancerspectrum.oupjournals.org/jnci/content/vol96/
issue6. If FPRP < 0.20, we think the association is reli-
able. Given that the gene mutation was regarded as cau-
sal, we used population-attributable risk (PAR) to refer
to the proportion of disease risk in a population that
can be attributed to the causal effects of the risk allele.
PAR can be assessed by using the formula [29].
Results
Eligible studies
By searching data, we found that 15 articles [7-19,30,31]
used case-control or cohort design to explore the rela-
tionship between HFE mutation and HCC. Six studies
[7,9,13,18,19,30] were excluded either because of insuffi-
cient numbers of samples or because they did not pro-
vide concrete genotype data. Altogether, nine studies
[8,10-12,14-17,31] which contained 1102 cases and 3766
controls met the inclusion criteria and were included in
the final analysis. Eight studies were published in Eng-
lish and one study was published in Spanish[16]. Five
studies [8,12,14,16,17] used peripheral blood leucocytes,
two studies used liver tissue [10,31]and two studies used
both blood and liver tissue [11,15] to extract genome
DNA. All studies used validated methods to genotype
the C282Y and or H63D mutation. Seven studies
[7-9,11,12,14,16,17,31] used PCR-RFLP, one study [10]
used the Taqman method, and one study [15] used PCR
combined with 3’minor groove binding group (MGB)
probe fluorescent hybridization. Of the nine studies,
eight studies (including 958 cases and 2258 controls)
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(Table 1).
All studies were published between 2000 and 2008. In
all studies, the cases were histologically confirmed or
d i a g n o s e db ye l e v a t e dA F Pa n dd i s t i n c ti c o n o g r a p h y
changes (CT, MRI, and B ultrasonography). All the con-
trols were free of cancer. The characteristics of the con-
trols varied across studies: five studies [8,11,12,15,17]
used CLD patients (four studies used LC patients as
controls and one study used HCV CH as controls) and
seven studies [8,10-12,14,16,31] included healthy popula-
tion as controls. LC was diagnosed according to clinical
and iconography changes. LC was classified as alcoholic
LC and viral LC according to clinical and virology data.
HCV was the main etiology of CLD in five studies and
only a small proportion of CLD was caused by
HBV. Studies were conducted in different ethnicities,
mainly in European populations; eight studies
[8,10-12,15-17,31] were conducted in populations of
European ethnicity, and one study [14] was conducted
in Marco Africans. The Hardy-Weinberg equilibrium
(HWE) p values of C282Y or H63D genotypes were
below 0.05 in the controls of three studies [8,12,17].
The disequilibrium might be caused by population stra-
tification or by genotyping errors. The meta-analysis
results were then assessed by excluding these studies.
Meta-analysis results
C282Y
The frequency of the C282Y Y allele was 6.17% (136/
2204) and 5.08% (383/7352) in cases and controls (p =
0.046), respectively, indicating that the variant allele was
more frequent in cases.
At first, we performed the meta-analysis of nine stu-
dies including all controls to explore the association of
C282Y polymorphism and HCC. Meta-analysis showed
that C282Y polymorphism was associated with HCC in
allele contrast model (Y vs. C): FE OR reached 1.50
(95%CI: 1.05-2.14) (Figure 1) (Table 2). There was
distinct heterogeneity among studies (p for heterogene-
ity = 0.02, I
2 = 0.57). Sensitivity analysis showed that the
result was not robust. There was no distinct small-study
bias among the studies (Egger’s p = 0.39). The meta-
analysis of dominant model showed a non-significant
increased risk to HCC: RE OR was 1.43 (95%CI: 0.98-
2.07, p for heterogeneity = 0.02, I
2 = 0.55). There was
no distinct small-study bias among the studies (Egger’s
p = 0.68).
Of the nine studies that explored C282Y mutation,
seven studies used healthy controls, while five studies
used chronic liver disease patients as controls. To clarify
whether or not C282Y increased HCC in subgroups, we
performed subgroup analyses between the comparison
of (1) HCC and healthy controls of seven studies, (2)
HCC and alcoholic LC patients of four studies, (3) HCC
and viral LC patients of four studies.
(1) When comparing C282Y polymorphisms between
HCC cases and healthy controls of seven studies, allele
contrast (Y vs. C) showed association with HCC: RE OR
reached 1.61 (95%CI: 1.08-2.39) (figure 2) (Table 2).
There was heterogeneity among studies (p for heteroge-
neity = 0.04, I
2 = 0.55). Sensitivity analysis showed that
the result was also not robust (figure not shown).
There was no small-study bias among the studies
(Egger’s p = 0.65).
(2) Four studies used alcoholic LC patients as controls.
Four studies included 224 HCC patients with alcoholic
LC and 380 alcoholic LC patients without HCC. Meta-
analysis provided more distinct association of C282Y
polymorphism with HCC among alcoholic LC patients.
FE OR reached 4.06 (95%CI: 2.08-7.92, p for heteroge-
neity = 0.77, I
2 = 0) in the dominant model (Figure 3),
and 3.41(95%CI: 1.81-6.41, p for heterogeneity = 0.47, I
2
= 0) as allele Y compared with allele C, respectively
(Table 2). Sensitivity analyses of two models both gave
robust results. Figure 4 showed the sensitivity analysis of
the dominant model. There was no small-study bias
(Egger’s p: 0.25-0.43).
Table 1 Main characteristics of all studies included in the meta-analysis
C282Y H63D
Author Year Country Study design Cases/Controls cases controls cases controls
CC CY YY CC CY YY HH HD DD HH HD DD
Ezzkiouri 2008 Maroc Case-control 96/222 95 1 0 219 3 0 59 34 3 160 60 2
Nahon 2008 France Cohort 103/198 91 12 0 180 18 0 75 28 0 149 49 0
Repero 2007 Spain Case-control 196/181 183 12 1 158 23 0 102 85 9 124 52 5
Willis 2005 England Case-control 144/1508 119 17 8 1331 168 9
Hellerbrand 2003 Germany Case-control 137/233 120 17 0 223 10 0 108 27 2 177 52 4
Cauza 2003 Austria Case-control 162/671 139 18 5 603 63 5 128 31 3 529 133 9
Boige 2003 France Case-control 133/100 126 7 0 93 6 1 92 41 0 59 40 1
Lauret 2002 Spain Case-control 77/359 65 12 0 337 22 0 52 25 0 234 92 33
Beckman 2000 Sweden Case-control 54/294 43 10 1 255 38 1 37 17 0 229 59 6
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patients as controls (including 160 case and 203 controls)
showed both dominant model and allele contrast had a
non-significantly decreased risk of HCC (FE OR = 0.70,
95%CI: 0.32-1.50 and FE OR = 0.71, 95%CI: 0.34-1.50,
respectively). There was no small-study bias among stu-
dies (Egger’s p = 0.51 and 0.52, respectively) and no het-
erogeneity among studies (I
2 = 0) (figure not shown).
H63D
Eight studies (included 958 cases and 2258 controls)
provided H63D genotype data. Variant D allele fre-
quency was 16.81% (322/1916) in cases and 14.32%
(657/4516) in controls, respectively.
Overall, this meta-analysis did not show H63D poly-
morphisms had influence on HCC occurrence. FE OR
was 1.19 (95%CI: 0.90-1.58, p for heterogeneity = 0.01,
I
2 = 0.60) and1.08 (95%CI: 0.83-1.39, p for heterogeneity
= 0.01, I
2 = 0.61) in the dominant model and allele con-
trast model, respectively (figure not shown). There was
no small-study bias among studies (Egger’s p = 0.62 and
0.34, respectively). We also performed subgroup meta-
analysis according to the characteristics of controls
(healthy controls and chronic liver diseases controls),
but all genetic models did not show evidence of associa-
tions with HCC (detailed data not shown).
The statistic power is an important issue on gene-dis-
ease association study. As for the association between
C282Y polymorphism with HCC among alcoholic LC
patients, we used the allele contrast (Y vs. C) data to calcu-
late the power. According to the parameters (frequency of
the mutation allele Y in the controls was 0.022, case num-
ber was 224 and control number was 380, pooled OR was
3.41, a = 0.05), PS software gave a power of 0.82, which
was satisfactory. However, power of the association study
on HCC and viral LC patients (160 cases and 203 controls,
frequency of variant allele Y = 0.05, pooled OR = 0.71,
a = 0.05) was very low (0.09).
By using the results of the meta-analysis (ORs and
95%CIs) and the knowledge of the epidemiological data
of HCC (prior probability) in different populations, we
Table 2 Meta-analysis results of C282Y polymorphism and HCC
Nine studies of all samples Seven studies of healthy
controls
Four studies of alcoholic
LC
Four studies of viral LC
Genetic model Dominant Allele contrast CY vs. CC Dominant Allele contrast Dominant Allele contrast Dominant Allele contrast
OR 1.43 1.50 1.31 1.46 1.61 4.06 3.41 0.70 0.71
95%CI 0.98-2.07 1.05-2.14 0.89-1.95 0.96-2.22 1.08-2.39 2.08-7.92 1.81-6.41 0.32-1.50 0.34-1.50
p for hetero 0.02 0.02 0.02 0.04 0.04 0.77 0.47 0.47 0.49
I
2 0.55 0.57 0.56 0.54 0.55 0 0 0 0
Egger’s p 0.31 0.39 0.99 0.97 0.65 0.25 0.43 0.51 0.52
Figure 1 Forest plot of the RE ORs and 95% CIs of the association between HCC and the C282Y mutation (Y vs. C) of nine studies. The
combined estimate is indicated by the diamond. The solid vertical line represents the null result.
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OR of allele contrast (Y vs. C) equaled 3.41 (95%CI:
1.81-6.41) in the subgroup analysis of four studies using
alcoholic LC controls. If the prior probability of devel-
oping HCC in alcoholic LC patients is assigned at 0.01,
then FPRP was 0.03 (<0.20).
Given that mutation allele Y of C282Y is a risk factor
of HCC, we further calculated PAR and its’ 95%CI in all
populations and in alcoholic LC patients. According to
the formula from Bruzzi, PAR of allele Y is 2.48% (95%
CI: 1.30%-3.65%) and 5.12% (2.57%-7.67%) in all popula-
tions and in alcoholic LC patients, respectively.
Figure 2 Forest plot of the RE ORs and 95% CIs of the studies on the association between HCC and the HFE C282Y mutation (Y vs. C)
of seven studies (using healthy controls).
Figure 3 Forest plot of the FE ORs and 95% CIs of the studies on the association between HCC and the HFE C282Y mutation (YY+CY
Vs. CC) of four studies (using alcoholic LC controls).
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HH is a common genetic disease in European popula-
tions that causes an inappropriately high absorption of
iron, leading to the progressive accumulation of iron in
the liver. The two missense mutations C282Y of the
HFE gene explain most of the cases of HH, a condition
characterized by hepatic iron overload. Liver iron accu-
mulation leads to reactive oxygen species formation in
the liver, thus causing oxidative stress. It has been
shown that the wild-type HFE protein forms a stable
complex with the transferrin (TF) receptor (TFR),
thereby reducing its affinity for TF [32], whereas the
HFE 282Tyr mutation almost completely prevents the
formation of a complex between the mutant HFE pro-
tein and the TFR, allowing a high-affinity TF binding to
the TFR. This binding results in an increased cellular
uptake of iron. A second missense mutation in the HFE
gene, H63D, is found in about 4% of patients with HH,
but its role in iron overload is still debated [6].
It has been reported that HCC occurred more in HH
patients than in normal populations in some cohort stu-
dies [4,33,34]. However, there are also opposite reports
that HH had low penetrance and did not increase the
risk of HCC [20,35,36].
From the late 1990s, many researchers have explored
the relationship between these two mutations and HCC
susceptibility by using case-control or cohort studies
[7-9,11-19,30]. In 2007, Christina Ellervik and her col-
leagues [37] performed a meta-analysis to examine asso-
ciations between C282Y and H63D mutations with
HCC. The meta-analysis included nine studies and
reported that C282Y homozygotes YY versus CC
obtained an odds ratio of 11 to HCC occurrence. How-
ever, the sample sizes of many studies included in that
meta-analysis were too small, leading to low statistical
power. From then on, several articles about HFE muta-
tions and HCC have been published. We selected nine
eligible studies including 1102 cases and 3766 controls
to conduct an updated meta-analysis.
Because HH is more frequent in northern European
populations, the studies on HFE gene mutations and
HCC are mainly come from European ethnicities. In
this meta-analysis, eight studies were come from Europe
and one from Africa. So, the analysis results may be
mainly applicable to European populations and it war-
rants to be studied in other ethnicities. In this meta-ana-
lysis, the frequency of C282Y YY homozygotes was
0.42% (16/3766), and the frequency of CY heterozygotes
was 9.32% (351/3766) in all control subjects. The geno-
type distribution was consistent with the dbSNP data.
H63D genotype distribution was 2.66% (60/2258) and
23.78% (537/2258) for DD homozygotes and HD hetero-
zygotes in controls, respectively.
As to C282Y, the ORs of allele contrast (Y vs. C) in
the six studies [8,10-12,15,31] were larger than 1.0.
Among the six studies, four studies [8,10-12] reported a
significant association between HCC and the C282Y
polymorphism (ORs > 1.0, 95%CIs did not include 1.0).
Because the frequency of the homozygous mutation of
C282Y is very low, and a large proportion of C282Y
Figure 4 Sensitivity analysis of the association of C282Y (YY+CY vs. CC) and HCC among alcoholic LC patients of four studies, in
which the meta-analysis estimates were computed omitting one study at a time. The results indicated the association was robust.
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treatment, such as venesection before developing LC or
HCC, the conclusion that YY homozygotes increased
HCC risk may have little clinical value. Thus, we only
explored the dominant model and allele contrast in this
meta-analysis. This meta-analysis proved that C282Y
mutation was associated with HCC in European popula-
tions, especially in alcoholic LC patients but not in viral
LC patients. This result is consistent with the results of
three previous studies [8,15,38], and it may implicate
that the hepatocarcinogenesis of alcoholic LC and viral
LC is different and warrants further study. Some studies
e x p l o r e dt h er o l eo fg e n d e ri nt h ei n f l u e n c eo ft h er e l a -
tionship between HFE gene and HCC [10,14,34] and
found that C282Y homozygotes YY mutation increased
the risk of HCC in male patients. One English study
[10] reported that male C282Y homozygotes were more
likely to be diagnosed with HCC (OR = 14, 95%CI: 5-
37), and the penetrance of the C282Y homozygous gen-
otype, with respect to HCC, was between 1.31% and
2.1% for males and zero for females. Another study [36]
reported that C282Y homozygote males had a relative
risk (RR) of about 23 for HCC occurrence, and the
penetrance, with respect to HCC, was 5.56%. As there
were few studies that provided concrete gender sub-
group genotype values, we could not make a pooled
analysis.
From the pooled genotype data, we could assess the
statistical power under various subgroup analyses using
PS software [27]. We noted that the power was satisfac-
tory except when comparisons were performed between
HCC cases and viral LC patients (power = 0.09). This
indicated that the null association of C282Y and HCC
when compared in HCC cases and viral LC cases should
be taken with caution and that it warranted further study
in a larger scale. FPRP is a valuable criterion to assess
whether or not a positive discovery came about by
chance. We used FPRP to assess the positive association
attained by this meta-analysis. The association between
C282Y (Y vs. C) and HCC attained by subgroup analysis
of four studies using alcoholic LC patients as controls
was proved to be reliable (FPRP = 0.03).
Population-attributable risk (PAR) is a valuable para-
meter to assess the influence of risk factors on disease
occurrence. The PAR of the variant allele Y of C282Y
among alcoholic LC patients was 5.12% (95%CI: 2.57%-
7.67%). This result suggested that the role of C282Y
polymorphism on HCC occurrence was modest.
Conclusions
This meta-analysis proved that C282Y mutation was
associated with HCC in European alcoholic LC patients.
The role of C282Y polymorphism on HCC occurrence
was modest. The association of this polymorphism and
HCC is warranted further studies in large scale includ-
ing diverse ethnicities. The molecular mechanism of the
different effect of C282Y on alcoholic LC and viral LC,
with respect to HCC occurrence, also merits further stu-
dies. This meta-analysis did not find association of
H63D mutation with HCC.
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